Focal Interest
Focal Interest

Cardiovascular Issues in Pregnancy

External reference: https://openalex.org/T12230

  1. Hypertensive pregnancy linked to higher cardiac biomarker levels
    Cross-sectional study of 312 pregnant women reveals progressive elevation of cardiac biomarkers including NT-proBNP and troponin-I across severity spectrum of hypertensive disorders.
  2. Pregnancy-related coronary microvascular dysfunction remains poorly understood
    CMD prevalence among pregnant women remains underrecognized; diagnostic methods and management approaches require pregnancy-specific validation and standardization to improve clinical outcomes.
  3. Women with aortic stenosis face sex-specific care gaps
    Sex-based disparities in aortic stenosis pathophysiology, diagnosis, and clinical management in women require tailored investigational approaches and lifetime disease management strategies.
  4. CT angiography identified coronary artery anomalies and their patterns
    Retrospective CCTA analysis of 2,786 patients identifies coronary artery anomalies in 1.82%, with high RCA take-off predominating and gender-specific variations in malignant courses documented.
  5. Women reported adverse experiences after conversion to general anesthesia
    Qualitative study examining women's experiences of general anesthesia conversion during cesarean delivery with inadequate neuraxial anesthesia and psychological outcomes.
  6. Maternal ischemic stroke linked to lasting cardiovascular burden
    Long-term study reveals favorable functional recovery in women after maternal ischemic stroke, but persistent cardiovascular burden and occupational impact remain significant clinical concerns.
  7. West-Norwegian PPCM incidence was low; recovery was successful
    Peripartum cardiomyopathy incidence, risk factors, and long-term clinical outcomes in a West-Norwegian population with comprehensive assessment of left ventricular recovery patterns.
  8. Ugandan women with peripartum cardiomyopathy had high mortality
    Prospective Ugandan cohort (n=80) with PPCM: baseline severe LV dysfunction, 7.5% six-month mortality, 10% intracardiac thrombus, 46.3% LV recovery; two-thirds received bromocriptine.